Previous 10 | Next 10 |
Investing in turnaround stocks takes a special kind of investor. Bruised businesses are rarely at the top of the list of stocks that people want to buy, and pretty much every turnaround story is fraught with the risk of potentially fatal failure. And those risks are looming large in I...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood’s infatuation with Ginkgo Bioworks (NYSE: DNA ) stock continued this week. The ARK Invest fund manager purchased an additional 1.13 million shares of the gene editing company on Thursday, adding t...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: nevodka / Shutterstock.com 23andMe (NASDAQ: ME ) is preparing for a major change at the executive level. Today, the firm announced that CFO Steven Schoch is planning to resign . Schoch had held the r...
The past few weeks have been refreshing for Cathie Wood and fans of her style of growth stock investing. The CEO and co-founder of Ark Invest publishes the buys and sells of her firm's exchange-traded funds (ETFs) every market day, giving the public insight into her latest allocation strate...
Direct-to-consumer genetic testing via online platforms arouses some skepticism but appears to be a profitable venture in the US anyway. Invitae Corporation could benefit from rising public awareness of direct-to-consumer genetic testing, but the company must streamline activities. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood’s Ark Invest has performed well recently, with shares of her flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT: ARKK ), up more than 15% during the past month. The performance w...
For medical genetics specialist Invitae 's (NYSE: NVTA) downtrodden investors, there was a lot riding on the company's second-quarter earnings release. An 85% share decline year to date can impart a make-or-break feeling to a fiscal report. As always, whether the results were a ...
Shares of Invitae (NYSE: NVTA) recently shot up like a rocket in response to a second-quarter earnings call that was a lot more positive than expected. The medical genetics company is still losing money, but it's starting to look like it can achieve a sustainable level of profitabil...
Invitae Corporation (NYSE: NVTA) , which specializes in medical genetic testing, saw its shares climb as high as 23% this week, according to data from S&P Global Intelligence . The stock closed at $2.30 last Friday, then opened on Monday at $2.37. It hit is weekly high at $9...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...